REDWOOD CITY, Calif.,
July 1, 2019 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised settings,
today announced that the Company has been added as a member
of the Russell 2000® and Russell
3000® Indexes effective at the opening of trading
today, July 1, 2019.
"We're pleased to be included in these widely followed indexes
which raises our visibility with institutions and investors, and
reflects the progress we have made as a commercial stage company,"
said Vince Angotti, Chief Executive
Officer at AcelRx.
The annual reconstitution of the Russell indexes captures the
4,000 largest U.S. stocks as of May
10, ranking them by total market
capitalization. Membership in the Russell 3000 Index, which
remains in place for one year, means automatic inclusion in the
large-cap Russell 1000® Index or small-cap Russell
2000 Index as well as the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings and style
attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets are benchmarked against
Russell's U.S. indexes. Russell indexes are part of FTSE Russell, a
leading global index provider. For more information on the Russell
2000 and 3000 Indexes and the Russell indexes reconstitution, go to
the "Russell Reconstitution" section on the FTSE Russell
website.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S., DSUVIA (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
one product candidate, Zalviso®(sufentanil sublingual
tablet system, SST system, 15 mcg), being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings. DZUVEO and Zalviso are both approved products in
Europe. Zalviso is an
investigational drug and not approved in the U.S. For additional
information about AcelRx, please visit www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-added-to-the-russell-2000-and-3000-indexes-300878743.html
SOURCE AcelRx Pharmaceuticals, Inc.